-DOCSTART-	O

Title	O
:	O
[	O
Human	B-I
Albumin	I-I
Grifols	I-I
5	O
%	O
in	O
plasmapheresis	O
:	O
a	O
new	O
therapy	O
involving	O
beta	O
-	O
amyloid	O
mobilisation	O
in	O
Alzheimer	O
'	O
s	O
disease	O
]	O
.	O

-DOCSTART-	O

Title	O
:	O
Effectiveness	O
and	O
tolerability	O
of	O
high	B-I
-	I-I
dose	I-I
(	I-I
23	I-I
mg	I-I
/	I-I
d	I-I
)	I-I
versus	O
standard	B-I
-	I-I
dose	I-I
(	I-I
10	I-I
mg	I-I
/	I-I
d	I-I
)	I-I
donepezil	I-I
in	O
moderate	O
to	O
severe	O
Alzheimer	O
'	O
s	O
disease	O
:	O
A	O
24	O
-	O
week	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
study	O
.	O

METHODS	O
:	O
This	O
randomized	O
,	O
double	O
-	O
blind	O
study	O
was	O
conducted	O
at	O
219	O
sites	O
in	O
Asia	O
,	O
Europe	O
,	O
Australia	O
,	O
North	O
America	O
,	O
South	O
Africa	O
,	O
and	O
South	O
America	O
from	O
June	O
6	O
,	O
2007	O
,	O
to	O
March	O
27	O
,	O
2009	O
.	O

Patients	B-P
aged	I-P
45	I-P
to	I-P
90	I-P
years	I-P
with	I-P
probable	I-P
AD	I-P
,	I-P
Mini	I-P
-	I-P
Mental	I-P
State	I-P
Examination	I-P
score	I-P
0	I-P
to	I-P
20	I-P
(	I-P
moderate	I-P
to	I-P
severe	I-P
impairment	I-P
)	I-P
,	I-P
and	I-P
who	I-P
were	I-P
receiving	I-P
donepezil	I-P
10	I-P
mg	I-P
once	I-P
daily	I-P
for	I-P
>	I-P
or	I-P
=12	I-P
weeks	I-P
before	I-P
the	I-P
start	I-P
of	I-P
the	I-P
study	I-P
were	O
eligible	O
.	O

Patients	O
(	O
n	O
=	O
1467	O
)	O
were	O
randomly	O
assigned	O
to	O
receive	O
high	B-I
-	I-I
dose	I-I
donepezil	I-I
(	O
23	O
mg	O
once	O
daily	O
)	O
or	O
standard	B-I
-	I-I
dose	I-I
donepezil	I-I
(	O
10	O
mg	O
once	O
daily	O
)	O
for	O
24	O
weeks	O
.	O

Coprimary	O
effectiveness	O
measures	O
were	O
changes	O
in	O
cognition	B-O
and	O
global	B-O
functioning	I-O
,	O
as	O
assessed	O
using	O
least	O
squares	O
mean	O
changes	O
from	O
baseline	O
(	O
LSM	O
[	O
SE	O
]	O
A	O
)	O
scores	O
(	O
last	O
observation	O
carried	O
forward	O
)	O
on	O
the	B-O
Severe	I-O
Impairment	I-O
Battery	I-O
(	I-O
SIB	I-O
;	I-O
cognition	I-O
)	I-O
and	O
the	B-O
Clinician	I-O
'	I-O
s	I-O
Interview	I-O
-	I-O
Based	I-O
Impression	I-O
of	I-O
Change	I-O
Plus	I-O
Caregiver	I-O
Input	I-O
scale	I-O
(	I-O
CIBIC	I-O
+	I-O
;	I-O
global	I-O
function	I-O
rating	I-O
)	I-O
overall	O
change	O
score	O
(	O
mean	O
[	O
SD	O
]	O
)	O
at	O
week	O
24	O
.	O

Treatment	B-O
-	I-O
emergent	I-O
adverse	I-O
events	I-O
(	I-O
TEAEs	I-O
)	I-O
were	O
assessed	O
using	O
spontaneous	B-O
patient	I-O
/	I-O
caregiver	I-O
reporting	I-O
and	O
open	B-O
-	I-O
ended	I-O
questioning	I-O
;	O
clinical	B-O
laboratory	I-O
testing	I-O
(	O
hematology	B-O
,	O
biochemistry	B-O
,	O
and	O
urinalysis	B-O
panels	I-O
analyzed	O
by	O
a	O
central	O
laboratory	O
)	O
;	O
12	B-O
-	I-O
lead	I-O
ECG	I-O
;	O
and	O
physical	B-O
and	O
neurologic	B-O
examinations	I-O
,	O
including	O
vital	B-O
sign	I-O
measurements	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Assessing	O
the	O
cost	O
-	O
effectiveness	O
of	O
the	B-I
rivastigmine	I-I
transdermal	I-I
patch	I-I
for	O
Alzheimer	O
'	O
s	O
disease	O
in	O
the	O
UK	O
using	O
MMSE	O
-	O
and	O
ADL	O
-	O
based	O
models	O
.	O

METHODS	O
:	O
Incremental	B-O
costs	I-O
and	O
Quality	B-O
Adjusted	I-O
Life	I-O
Years	I-O
(	I-O
QALYs	I-O
)	I-O
associated	O
with	O
rivastigmine	B-I
patch	I-I
and	O
capsule	B-I
treatment	I-I
versus	O
best	B-C
supportive	I-C
care	I-C
(	I-C
BSC	I-C
)	I-C
were	O
calculated	O
using	O
two	O
economic	O
models	O
,	O
one	O
based	O
solely	O
on	O
Mini	B-O
-	I-O
Mental	I-O
State	I-O
Examination	I-O
(	I-O
MMSE	I-O
)	I-O
scores	I-O
,	O
and	O
one	O
also	O
incorporating	O
activities	B-O
of	I-O
daily	I-O
living	I-O
(	I-O
ADL	I-O
)	I-O
scores	I-O
.	O

The	O
clinical	O
pathway	O
was	O
populated	O
with	O
data	O
from	O
a	O
clinical	O
trial	O
of	O
rivastigmine	B-I
patch	I-I
(	O
9	O
.	O
5	O
mg	O
/	O
24	O
h	O
)	O
and	O
capsules	B-I
(	O
12	O
mg	O
/	O
day	O
)	O
versus	O
placebo	B-C
.	O

Costs	O
were	O
based	O
on	O
the	O
UK	O
health	O
and	O
social	O
care	O
costs	O
and	O
basic	O
UK	O
National	O
Health	O
Service	O
(	O
NHS	O
)	O
prices	O
.	O

Disease	O
progression	O
was	O
modelled	O
beyond	O
the	O
trial	O
period	O
over	O
5	O
years	O
using	O
published	O
equations	O
to	O
predict	O
natural	O
decline	O
in	O
AD	O
patients	O
.	O

Base	O
case	O
costing	O
variables	O
included	O
drugs	O
,	O
clinical	O
monitoring	O
,	O
and	O
institutionalization	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
effects	O
on	O
cognitive	O
functions	O
of	O
a	B-I
movement	I-I
-	I-I
based	I-I
intervention	I-I
in	O
patients	B-P
with	I-P
Alzheimer	I-P
'	I-P
s	I-P
type	I-P
dementia	I-P
:	O
a	O
pilot	O
study	O
.	O

METHODS	O
:	O
The	O
sample	O
consisted	O
of	O
27	B-P
patients	I-P
fulfilling	I-P
the	I-P
AD	I-P
ICD	I-P
-	I-P
10	I-P
diagnostic	I-P
criteria	I-P
.	O

The	O
patient	O
sample	O
was	O
randomly	O
divided	O
into	O
two	O
groups	O
:	O
The	B-I
Exercise	I-I
Group	O
received	O
6	B-I
weeks	I-I
movement	I-I
training	I-I
and	O
comprised	O
15	O
participants	O
with	O
a	O
mean	O
age	O
of	O
70	O
.	O
5	O
years	O
(	O
SD	O
:	O
8	O
)	O
.	O

Control	O
Group	O
participated	O
in	O
a	B-C
standard	I-C
care	I-C
group	O
,	O
which	O
served	O
as	O
a	O
control	O
intervention	O
,	O
and	O
consisted	O
of	O
12	O
patients	O
with	O
an	O
average	O
age	O
of	O
75	O
.	O
7	O
years	O
(	O
SD	O
:	O
6	O
.	O
90	O
)	O
.	O

Cognitive	B-O
functions	I-O
were	O
assessed	O
using	O
six	B-O
computerised	I-O
tests	I-O
from	I-O
the	I-O
CANTAB	I-O
,	O
pre	O
and	O
post	O
training	O
.	O

Data	O
were	O
analysed	O
using	O
t	O
-	O
tests	O
.	O

The	O
false	O
discovery	O
rate	O
(	O
FDR	O
)	O
for	O
multiple	O
comparisons	O
as	O
well	O
as	O
Cohen	O
'	O
s	O
d	O
effect	O
size	O
was	O
used	O
to	O
assess	O
the	O
significant	O
effects	O
.	O

-DOCSTART-	O

Title	O
:	O
EHT0202	B-I
in	O
Alzheimer	O
'	O
s	O
disease	O
:	O
a	O
3	O
-	O
month	O
,	O
randomized	O
,	O
placebo	O
-	O
controlled	O
,	O
double	O
-	O
blind	O
study	O
.	O

METHODS	O
:	O
This	O
pilot	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
parallel	O
group	O
,	O
multicentre	O
,	O
Phase	O
IIA	O
study	O
was	O
conducted	O
in	O
159	B-P
randomized	I-P
patients	I-P
suffering	I-P
from	I-P
mild	I-P
to	I-P
moderate	I-P
Alzheimer	I-P
'	I-P
s	I-P
Disease	I-P
.	O

EHT0202	B-I
(	O
40	O
or	O
80	O
mg	O
bid	O
)	O
or	O
placebo	B-C
was	O
administered	O
as	O
adjunctive	O
therapy	O
to	O
one	B-I
acetylcholinesterase	I-I
inhibitor	I-I
over	O
a	O
3	O
-	O
month	O
period	O
.	O

This	O
study	O
was	O
designed	O
to	O
assess	O
the	O
clinical	B-O
safety	I-O
and	O
tolerability	B-O
of	O
EHT0202	B-I
as	O
a	O
primary	O
objective	O
,	O
with	O
secondary	O
endpoints	O
(	O
cognitive	B-O
function	I-O
,	O
daily	B-O
living	I-O
activities	I-O
,	O
behaviour	B-O
,	O
caregiver	B-O
burden	I-O
and	O
global	B-O
functioning	I-O
)	O
included	O
to	O
explore	O
clinical	O
efficacy	O
of	O
EHT0202	B-I
versus	O
placebo	B-C
.	O

-DOCSTART-	O

Title	O
:	O
Dose	O
effects	O
associated	O
with	O
rivastigmine	B-I
transdermal	I-I
patch	I-I
in	O
patients	B-P
with	I-P
mild	I-P
-	I-P
to	I-P
-	I-P
moderate	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
.	O

METHODS	O
:	O
This	O
was	O
a	O
retrospective	O
analysis	O
of	O
a	O
large	O
,	O
international	O
,	O
24	O
-	O
week	O
,	O
randomised	O
,	O
placebo	O
-	O
and	O
active	O
-	O
controlled	O
trial	O
(	O
IDEAL	O
,	O
CENA713D2320	O
)	O
of	O
rivastigmine	B-I
in	O
patients	B-P
with	I-P
mild	I-P
-	I-P
to	I-P
-	I-P
moderate	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
(	I-P
AD	I-P
)	I-P
.	O

Patients	O
received	O
the	B-I
9	I-I
.	I-I
5	I-I
mg	I-I
/	I-I
24	I-I
h	I-I
rivastigmine	I-I
patch	I-I
,	O
the	B-I
17	I-I
.	I-I
4	I-I
mg	I-I
/	I-I
24	I-I
h	I-I
rivastigmine	I-I
patch	I-I
,	O
12	B-I
mg	I-I
/	I-I
day	I-I
rivastigmine	I-I
capsules	I-I
or	O
placebo	B-C
.	O

Changes	O
from	O
baseline	O
at	O
week	O
24	O
on	O
the	B-O
AD	I-O
Assessment	I-O
Scale	I-O
-	I-O
cognitive	I-O
subscale	I-O
(	I-O
ADAS	I-O
-	I-O
cog	I-O
)	I-O
,	O
AD	B-O
Cooperative	I-O
Study	I-O
-	I-O
Clinical	I-O
Global	I-O
Impression	I-O
of	I-O
Change	I-O
(	I-O
ADCS	I-O
-	I-O
CGIC	I-O
)	I-O
and	O
the	B-O
AD	I-O
Cooperative	I-O
Study	I-O
-	I-O
Activities	I-O
of	I-O
Daily	I-O
Living	I-O
(	I-O
ADCS	I-O
-	I-O
ADL	I-O
)	I-O
scale	I-O
were	O
calculated	O
based	O
on	O
the	O
patient	O
'	O
s	O
mode	O
and	O
last	O
prescribed	O
patch	O
dose	O
.	O

The	O
analysis	O
included	O
the	O
4	O
.	O
6	O
mg	O
/	O
24	O
h	O
and	O
13	O
.	O
3	O
mg	O
/	O
24	O
h	O
patch	O
doses	O
,	O
for	O
which	O
efficacy	O
data	O
have	O
not	O
previously	O
been	O
reported	O
.	O

-DOCSTART-	O

Title	O
:	O
Escitalopram	B-I
versus	O
risperidone	B-I
for	O
the	O
treatment	O
of	O
behavioral	O
and	O
psychotic	O
symptoms	O
associated	O
with	O
Alzheimer	O
'	O
s	O
disease	O
:	O
a	O
randomized	O
double	O
-	O
blind	O
pilot	O
study	O
.	O

METHODS	O
:	O
Inpatients	B-P
with	I-P
AD	I-P
,	I-P
who	I-P
had	I-P
been	I-P
hospitalized	I-P
because	I-P
of	I-P
behavioral	I-P
symptoms	I-P
,	O
were	O
recruited	O
to	O
a	O
six	O
-	O
week	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
controlled	O
trial	O
.	O

Participants	O
(	O
n	O
=	O
40	O
)	O
were	O
randomized	O
to	O
once	B-I
daily	I-I
risperidone	I-I
1	O
mg	O
or	O
escitalopram	B-I
10	O
mg	O
.	O

-DOCSTART-	O

Title	O
:	O
Tolerability	O
and	O
efficacy	O
of	O
memantine	B-I
add	I-I
-	I-I
on	I-I
therapy	I-I
to	O
rivastigmine	B-I
transdermal	I-I
patches	I-I
in	O
mild	O
to	O
moderate	O
Alzheimer	O
'	O
s	O
disease	O
:	O
a	O
multicenter	O
,	O
randomized	O
,	O
open	O
-	O
label	O
,	O
parallel	O
-	O
group	O
study	O
.	O

METHODS	O
:	O
In	O
this	O
multicenter	O
,	O
randomized	O
,	O
open	O
-	O
label	O
study	O
,	O
patients	O
entered	O
an	O
8	O
-	O
week	O
run	O
-	O
in	O
period	O
(	O
a	O
5	O
cm	O
2	O
rivastigmine	O
patch	O
for	O
4	O
weeks	O
,	O
then	O
a	O
10	O
cm	O
(	O
2	O
)	O
patch	O
for	O
4	O
weeks	O
)	O
followed	O
by	O
16	B-I
weeks	I-I
of	I-I
memantine	I-I
plus	O
rivastigmine	B-I
patch	I-I
or	O
rivastigmine	B-I
patch	I-I
monotherapy	I-I
.	O

The	O
primary	O
outcome	O
measure	O
was	O
the	B-O
retention	I-O
rate	I-O
at	O
the	O
end	O
of	O
the	O
trial	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
of	O
simvastatin	B-I
to	O
treat	O
Alzheimer	O
disease	O
.	O

METHODS	O
:	O
This	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
of	O
simvastatin	B-I
was	O
conducted	O
in	O
individuals	B-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
AD	I-P
and	I-P
normal	I-P
lipid	I-P
levels	I-P
.	O

Participants	O
were	O
randomly	O
assigned	O
to	O
receive	O
simvastatin	B-I
,	O
20	O
mg	O
/	O
day	O
,	O
for	O
6	O
weeks	O
then	O
40	O
mg	O
per	O
day	O
for	O
the	O
remainder	O
of	O
18	O
months	O
or	O
identical	B-C
placebo	I-C
.	O

The	O
primary	O
outcome	O
was	O
the	O
rate	O
of	O
change	O
in	O
the	B-O
Alzheimer	I-O
'	I-O
s	I-O
Disease	I-O
Assessment	I-O
Scale	I-O
-	I-O
cognitive	I-O
portion	I-O
(	I-O
ADAS	I-O
-	I-O
Cog	I-O
)	I-O
.	O

Secondary	O
outcomes	O
measured	O
clinical	B-O
global	I-O
change	I-O
,	O
cognition	B-O
,	O
function	B-O
,	O
and	O
behavior	B-O
.	O

METHODS	O
:	O
This	O
study	O
provides	O
Class	O
I	O
evidence	O
that	O
simvastatin	O
40	O
mg	O
/	O
day	O
does	O
not	O
slow	O
decline	O
on	O
the	O
ADAS	O
-	O
Cog	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
6	O
-	O
month	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
pilot	O
discontinuation	O
trial	O
following	O
response	O
to	O
haloperidol	B-I
treatment	I-I
of	O
psychosis	O
and	O
agitation	O
in	O
Alzheimer	O
'	O
s	O
disease	O
.	O

METHODS	O
:	O
In	O
outpatients	B-P
with	I-P
AD	I-P
with	I-P
symptoms	I-P
of	I-P
psychosis	I-P
or	I-P
agitation	I-P
,	I-P
responders	I-P
to	I-P
20	I-P
weeks	I-P
of	I-P
haloperidol	I-P
(	I-P
0	I-P
.	I-P
5	I-P
-	I-P
5	I-P
mg	I-P
daily	I-P
)	I-P
were	O
randomized	O
to	O
a	O
24	O
-	O
week	O
,	O
double	O
-	O
blind	O
pilot	O
trial	O
of	O
discontinuation	O
on	O
placebo	B-C
versus	O
continuation	B-I
haloperidol	I-I
.	O

Phase	O
A	O
response	O
criteria	O
were	O
minimum	O
50	O
%	O
reduction	O
in	O
three	B-O
target	I-O
symptoms	I-O
,	O
and	O
improvement	O
on	O
the	B-O
Clinical	I-O
Global	I-O
Impression	I-O
-	I-O
Change	I-O
(	I-O
CGI	I-O
-	I-O
C	I-O
)	I-O
score	I-O
for	O
psychosis	B-O
/	O
agitation	B-O
.	O

Phase	O
B	O
relapse	O
criteria	O
required	O
50	O
%	O
worsening	O
in	O
target	B-O
symptoms	I-O
and	O
on	O
the	B-O
CGI	I-O
-	I-O
C	I-O
.	O

?	O
=	O
0	O
.	O
1	O
was	O
the	O
significance	O
criterion	O
in	O
this	O
pilot	O
study	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
telmisartan	B-I
on	O
cognition	O
and	O
regional	O
cerebral	O
blood	O
flow	O
in	O
hypertensive	B-P
patients	I-P
with	I-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
.	O

METHODS	O
:	O
A	B-P
total	I-P
of	I-P
20	I-P
patients	I-P
with	I-P
probable	I-P
AD	I-P
and	I-P
essential	I-P
hypertension	I-P
were	O
randomly	O
assigned	O
to	O
the	B-I
telmisartan	I-I
group	O
(	O
n	O
=	O
10	O
,	O
40	O
-	O
80	O
mg	O
daily	O
)	O
or	O
the	B-I
amlodipine	I-I
group	O
(	O
n	O
=	O
10	O
,	O
5	O
-	O
10	O
mg	O
daily	O
)	O
for	O
6	O
months	O
.	O

-DOCSTART-	O

Title	O
:	O
Health	B-I
and	I-I
nutrition	I-I
promotion	I-I
program	I-I
for	O
patients	B-P
with	I-P
dementia	I-P
(	O
NutriAlz	O
)	O
:	O
cluster	O
randomized	O
trial	O
.	O

METHODS	O
:	O
Cluster	O
randomized	O
multi	O
-	O
centre	O
study	O
with	O
one	O
-	O
year	O
follow	O
-	O
up	O
.	O

11	O
Alzheimer	O
outpatients	O
and	O
day	O
care	O
centres	O
(	O
Barcelona	O
,	O
Spain	O
)	O
.	O

Nine	B-P
hundred	I-P
and	I-P
forty	I-P
six	I-P
home	I-P
-	I-P
living	I-P
Alzheimer	I-P
patients	I-P
with	I-P
identified	I-P
caregiver	I-P
were	O
consecutively	O
recruited	O
(	O
intervention	O
group	O
:	O
6	O
centres	O
,	O
448	O
patients	O
vs	O
control	O
group	O
:	O
5	O
centres	O
,	O
498	O
patients	O
)	O
.	O

The	O
intervention	O
was	O
a	B-I
teaching	I-I
and	I-I
training	I-I
intervention	I-I
on	I-I
health	I-I
and	I-I
nutrition	I-I
program	I-I
,	O
NutriAlz	O
,	O
directed	O
both	O
to	O
physician	O
and	O
main	O
caregiver	O
,	O
as	O
well	O
as	O
persons	O
affected	O
by	O
Alzheimer	O
'	O
s	O
disease	O
or	O
other	O
dementias	O
,	O
including	O
a	O
standardised	O
protocol	O
for	O
feeding	O
and	O
nutrition	O
.	O

The	O
main	O
outcome	O
measure	O
was	O
the	O
reduction	O
in	O
the	B-O
loss	I-O
of	I-O
autonomy	I-O
(	O
Activities	B-O
of	I-O
daily	I-O
living	I-O
(	I-O
ADL	I-O
/	I-O
IADL	I-O
)	I-O
scales	I-O
)	O
assessed	O
at	O
6	O
and	O
12	O
months	O
.	O

Secondary	O
outcomes	O
measures	O
were	O
Improvement	O
in	O
nutritional	B-O
status	I-O
(	O
Mini	B-O
Nutritional	I-O
Assessment	I-O
(	I-O
MNA	I-O
)	I-O
,	O
BMI	B-O
,	O
and	O
weight	B-O
changes	I-O
)	O
,	O
and	O
caregiver	B-O
burden	I-O
(	O
Zarit	B-O
scale	I-O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
and	O
safety	O
of	O
donepezil	B-I
23	O
mg	O
versus	O
donepezil	B-I
10	O
mg	O
for	O
moderate	O
-	O
to	O
-	O
severe	O
Alzheimer	O
'	O
s	O
disease	O
:	O
a	O
subgroup	O
analysis	O
in	O
patients	O
already	O
taking	O
or	O
not	O
taking	O
concomitant	O
memantine	O
.	O

METHODS	O
:	O
Prespecified	O
analysis	O
of	O
data	O
from	O
a	O
24	O
-	O
week	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
trial	O
.	O

Patients	O
were	O
randomized	O
to	O
donepezil	B-I
doses	O
(	O
23	O
vs	O
.	O
10	O
mg	O
/	O
day	O
)	O
and	O
stratified	O
by	O
concomitant	O
memantine	O
use	O
(	O
yes	O
or	O
no	O
)	O
.	O

Efficacy	O
and	O
safety	O
were	O
assessed	O
for	O
each	O
donepezil	B-I
dose	O
in	O
subgroups	O
taking	O
or	O
not	O
taking	O
concomitant	O
memantine	O
.	O

-DOCSTART-	O

Title	O
:	O
Nutritional	B-I
treatment	I-I
of	O
aged	B-P
individuals	I-P
with	I-P
Alzheimer	I-P
disease	I-P
living	I-P
at	I-P
home	I-P
with	I-P
their	I-P
spouses	I-P
:	O
study	O
protocol	O
for	O
a	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
AD	B-P
patients	I-P
and	I-P
their	I-P
spouses	I-P
(	I-P
aged	I-P
>	I-P
65	I-P
years	I-P
)	I-P
living	I-P
at	I-P
home	I-P
(	I-P
n	I-P
=	I-P
202	I-P
,	I-P
102	I-P
AD	I-P
patients	I-P
)	I-P
were	O
recruited	O
using	O
central	O
AD	O
registers	O
in	O
Finland	O
.	O

The	O
couples	O
were	O
randomized	O
into	O
intervention	O
and	O
control	O
groups	O
.	O

A	O
trained	O
nutritionist	O
visited	O
intervention	O
couples	O
4	O
-	O
8	O
times	O
at	O
their	O
homes	O
and	O
the	O
couples	O
received	O
tailored	B-I
nutritional	I-I
care	I-I
.	O

When	O
necessary	O
,	O
the	O
couples	O
were	O
given	O
protein	O
and	O
nutrient	O
-	O
enriched	O
complementary	O
drinks	O
.	O

All	O
intervention	O
couples	O
were	O
advised	O
to	O
take	O
vitamin	B-I
D	I-I
20	O
?g	O
/	O
day	O
.	O

The	O
intervention	O
lasted	O
for	O
one	O
year	O
.	O

The	O
couples	O
of	O
the	O
control	O
group	O
received	O
a	B-C
written	I-C
guide	I-C
on	O
nutrition	O
of	O
older	O
people	O
.	O

Participants	O
in	O
the	O
intervention	O
group	O
were	O
assessed	O
every	O
three	O
months	O
.	O

The	O
primary	O
outcome	O
measure	O
is	O
weight	B-O
change	I-O
.	O

Secondary	O
measures	O
are	O
the	B-O
intake	I-O
of	I-O
energy	I-O
,	O
protein	B-O
,	O
and	O
other	B-O
nutrients	I-O
,	O
nutritional	B-O
status	I-O
,	O
cognition	B-O
,	O
caregiver	B-O
'	I-O
s	I-O
burden	I-O
,	O
depression	B-O
,	O
health	B-O
related	I-O
quality	I-O
of	I-O
life	I-O
and	O
grip	B-O
strength	I-O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
combination	O
of	O
galantamine	B-I
and	O
memantine	B-I
modifies	O
cognitive	O
function	O
in	O
subjects	B-P
with	I-P
amnestic	I-P
MCI	I-P
.	O

METHODS	O
:	O
For	O
a	O
2	O
-	O
year	O
,	O
double	O
-	O
blinded	O
,	O
placebo	O
-	O
controlled	O
study	O
MCI	B-P
patients	I-P
,	I-P
presenting	I-P
with	I-P
an	I-P
amnestic	I-P
syndrome	I-P
but	I-P
not	I-P
necessarily	I-P
based	I-P
on	I-P
presumed	I-P
prodromal	I-P
AD	I-P
were	O
randomized	O
.	O

Patients	O
received	O
(	O
a	O
)	O
a	O
combination	O
of	O
16	B-I
mg	I-I
galantamine	I-I
plus	O
20	B-I
mg	I-I
memantine	I-I
,	O
or	O
(	O
b	O
)	O
16	B-I
mg	I-I
galantamine	I-I
alone	O
or	O
(	O
c	O
)	O
placebo	B-C
.	O

The	O
primary	O
objective	O
was	O
to	O
explore	O
the	O
differential	O
impact	O
of	O
these	O
interventions	O
on	O
the	B-O
progression	I-O
to	I-O
dementia	I-O
and	O
on	O
cognitive	B-O
changes	I-O
as	O
measured	O
by	O
the	B-O
ADAScog	I-O
.	O

